After years of treatment intensification, a new focus in metastatic hormone-sensitive prostate cancer is de-escalation. Trials like ADREAM are evaluating planned treatment interruptions for patients with excellent responses, aiming to provide 'treatment-free intervals' that improve quality of life without sacrificing efficacy.

In metastatic hormone-sensitive prostate cancer, many patients receive multiple subsequent therapies, making Overall Survival (OS) a difficult endpoint to achieve. Therefore, a large, meaningful improvement in radiographic progression-free survival (RPFS) is considered a critical and actionable outcome for patients.

Beyond primary endpoints, a clinically meaningful benefit of the neoadjuvant apalutamide regimen was a 30% reduction in the need for postoperative radiotherapy. The investigator highlights this as avoiding 'double local therapy' (surgery plus radiation), a scenario often linked to increased long-term urinary toxicity for patients.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

For younger, fit patients with high-risk localized prostate cancer, the PROTEUS study provides data for a new treatment paradigm: perioperative ADT with apalutamide surrounding a radical prostatectomy. This offers a compelling surgical-based alternative to standard radiation-focused therapies.

Traditional endpoints like progression-free survival (PFS) incentivize continuous treatment. The NCI group proposes "treatment-free survival," a novel metric that quantifies time spent *off* therapy. This endpoint better captures the patient experience and rewards treatments that provide durable responses after a finite course.

Early neoadjuvant trials in the 1990s failed to show clinical benefit because they included many low-risk patients and used less potent hormonal therapies. The PROTEUS trial's success was built on learning from this history by strictly enrolling high-risk patients and using a powerful androgen receptor pathway inhibitor (ARPI).

The PROTEUS trial used two pathologic endpoints. The investigator suggests Residual Cancer Burden (RCB), which measures cellularity, is a more meaningful reflection of response than just residual tumor size. The RCB endpoint showed a much larger treatment effect (30% vs. 11%) compared to the tumor size endpoint (9% vs. 1%).

For patients with oligometastatic disease who achieve a deep PSA response (e.g., to zero), oncologists consider finite treatment durations (e.g., 18-24 months) followed by observation. This "do less harm" approach challenges the standard of continuous therapy until progression, aiming for long-term treatment-free intervals.